On the other hand, our current data show VEGFA amplification in the tumours with high immune-ITH, indicating the potential therapeutic benefit of combining anti-angiogenesis agent and checkpoint blockade in advanced HCC as demonstrated in recent successful phase III trial (IMbrave150) using atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGFA)5. This evidence concerns the gene VEGFA and neoplasm.